Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.12
JAZZ's Cash to Debt is ranked lower than
95% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. JAZZ: 0.12 )
Ranked among companies with meaningful Cash to Debt only.
JAZZ' s Cash to Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.84 Max: No Debt
Current: 0.12
Equity to Asset 0.35
JAZZ's Equity to Asset is ranked lower than
82% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. JAZZ: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
JAZZ' s Equity to Asset Range Over the Past 10 Years
Min: -0.84  Med: 0.4 Max: 0.87
Current: 0.35
-0.84
0.87
Interest Coverage 9.68
JAZZ's Interest Coverage is ranked lower than
86% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. JAZZ: 9.68 )
Ranked among companies with meaningful Interest Coverage only.
JAZZ' s Interest Coverage Range Over the Past 10 Years
Min: 0.7  Med: 8.93 Max: 76.32
Current: 9.68
0.7
76.32
F-Score: 7
Z-Score: 2.39
M-Score: -2.34
WACC vs ROIC
10.44%
17.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 37.20
JAZZ's Operating margin (%) is ranked higher than
94% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. JAZZ: 37.20 )
Ranked among companies with meaningful Operating margin (%) only.
JAZZ' s Operating margin (%) Range Over the Past 10 Years
Min: -252.34  Med: 24.97 Max: 46.95
Current: 37.2
-252.34
46.95
Net-margin (%) 24.81
JAZZ's Net-margin (%) is ranked higher than
90% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. JAZZ: 24.81 )
Ranked among companies with meaningful Net-margin (%) only.
JAZZ' s Net-margin (%) Range Over the Past 10 Years
Min: -273.04  Med: 11.92 Max: 49.25
Current: 24.81
-273.04
49.25
ROE (%) 21.72
JAZZ's ROE (%) is ranked higher than
93% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. JAZZ: 21.72 )
Ranked among companies with meaningful ROE (%) only.
JAZZ' s ROE (%) Range Over the Past 10 Years
Min: 4.38  Med: 22.19 Max: 111.92
Current: 21.72
4.38
111.92
ROA (%) 9.48
JAZZ's ROA (%) is ranked higher than
90% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. JAZZ: 9.48 )
Ranked among companies with meaningful ROA (%) only.
JAZZ' s ROA (%) Range Over the Past 10 Years
Min: -113.42  Med: 5.97 Max: 64.21
Current: 9.48
-113.42
64.21
ROC (Joel Greenblatt) (%) 260.08
JAZZ's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. JAZZ: 260.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
JAZZ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5278.54  Med: 583.84 Max: 11377.93
Current: 260.08
-5278.54
11377.93
Revenue Growth (3Y)(%) 29.20
JAZZ's Revenue Growth (3Y)(%) is ranked higher than
81% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. JAZZ: 29.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
JAZZ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.3  Med: 29.7 Max: 47.7
Current: 29.2
-2.3
47.7
EBITDA Growth (3Y)(%) 29.30
JAZZ's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. JAZZ: 29.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
JAZZ' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 3.8  Med: 29.3 Max: 75.7
Current: 29.3
3.8
75.7
EPS Growth (3Y)(%) 6.40
JAZZ's EPS Growth (3Y)(%) is ranked higher than
60% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. JAZZ: 6.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
JAZZ' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.4  Med: 4.4 Max: 61.7
Current: 6.4
-66.4
61.7
GuruFocus has detected 5 Warning Signs with Jazz Pharmaceuticals PLC $JAZZ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» JAZZ's 10-Y Financials

Financials (Next Earnings Date: 2017-02-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

JAZZ Guru Trades in Q1 2016

Steven Cohen 74,500 sh (New)
Lee Ainslie 9,070 sh (New)
Jim Simons 215,100 sh (+1044.15%)
Paul Tudor Jones 13,552 sh (+99.65%)
Pioneer Investments 462,460 sh (+27.12%)
Joel Greenblatt 197,619 sh (+6.84%)
Ken Fisher 1,949 sh (+4.84%)
Louis Moore Bacon Sold Out
George Soros Sold Out
RS Investment Management 356,361 sh (-0.77%)
» More
Q2 2016

JAZZ Guru Trades in Q2 2016

George Soros 7,800 sh (New)
Andreas Halvorsen 618,862 sh (New)
Jim Simons 719,508 sh (+234.50%)
Steven Cohen 218,900 sh (+193.83%)
Paul Tudor Jones 26,549 sh (+95.90%)
Pioneer Investments 472,089 sh (+2.08%)
Ken Fisher 1,859 sh (-4.62%)
Lee Ainslie 8,210 sh (-9.48%)
RS Investment Management 313,728 sh (-11.96%)
Joel Greenblatt 105,404 sh (-46.66%)
» More
Q3 2016

JAZZ Guru Trades in Q3 2016

Steven Cohen 352,200 sh (+60.90%)
Joel Greenblatt 153,251 sh (+45.39%)
Pioneer Investments 643,783 sh (+36.37%)
Jim Simons 914,800 sh (+27.14%)
Andreas Halvorsen 737,623 sh (+19.19%)
Lee Ainslie 9,710 sh (+18.27%)
Ken Fisher 2,006 sh (+7.91%)
George Soros Sold Out
Paul Tudor Jones 18,157 sh (-31.61%)
» More
Q4 2016

JAZZ Guru Trades in Q4 2016

Jim Simons 1,560,300 sh (+70.56%)
Pioneer Investments 822,687 sh (+27.79%)
Lee Ainslie 12,240 sh (+26.06%)
Andreas Halvorsen Sold Out
Ken Fisher 1,896 sh (-5.48%)
Steven Cohen 243,100 sh (-30.98%)
Joel Greenblatt 81,417 sh (-46.87%)
Paul Tudor Jones 8,109 sh (-55.34%)
» More
» Details

Insider Trades

Latest Guru Trades with JAZZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ALKS, NAS:SGEN, NAS:UTHR, NAS:EXEL, NAS:TSRO, NAS:IONS, NAS:ACAD, OTCPK:NVZMY, NAS:ARIA, OTCPK:GMXAY, NAS:TECH, NAS:ALNY, NAS:GLPG, NAS:ICPT, NAS:RARE, NAS:CBPO, NAS:CLVS, NAS:BLUE, OTCPK:UCBJY, NYSE:XON » details
Traded in other countries:J7Z.Germany,
Jazz Pharmaceuticals PLC is a specialty pharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs.

Jazz Pharmaceuticals PLC was originally incorporated in California in March 2003 and was reincorporated in Delaware in January 2004. The Company was originally formed as a private limited liability company in March 2005 under the name Azur Pharma Limited, and was subsequently re-registered as a public limited company under the name Azur Pharma Public Limited Company in October 2011. On January 18, 2012, the business of Jazz Pharmaceuticals, Inc. and Azur Pharma were combined in the Azur Merger in connection with which Azur Pharma was re-named Jazz Pharmaceuticals plc. It is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. Its marketed products are: Xyrem, Erwinaze and Defitelio. Xyrem (sodium oxybate) oral solution, is a product approved by the U.S. Food and Drug Administration, or FDA, for the treatment of both cataplexy and excessive daytime sleepiness, or EDS, in patients with narcolepsy; Erwinaze (asparaginase Erwinia chrysanthemi) is a treatment approved in the U.S. and in certain markets in Europe (where it is marketed as Erwinase) for patients with acute lymphoblastic leukemia, or ALL, who have developed hypersensitivity to E. coli-derived asparaginase; and Defitelio (defibrotide) is a product approved in Europe for the treatment of severe hepatic veno-occlusive disease, or VOD, in adults and children undergoing hematopoietic stem cell transplantation, or HSCT, therapy. Its commercial operations are in the U.S. and Europe. In the U.S., Xyrem, is sold to one specialty pharmacy, Express Scripts, which ships Xyrem directly to patients. Erwinaze is sold to hospitals through a specialty distributor, McKesson Corporation. Prialt is sold in the U.S. through an exclusive pharmacy to other pharmacies and medical facilities, and other products are sold in the U.S. to distributors who distribute the product to pharmacies and hospitals. Its patents include Xyrem, Defitelio, amd Erwinaze. The manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, sale, distribution, record keeping, importing and exporting of products and research and development activities are subject to extensive regulation by the FDA, the EC the competent authorities of the EU member states and other regulatory authorities.

Top Ranked Articles about Jazz Pharmaceuticals PLC

Stocks Fisher Investments Has Bought for Past 2 Quarters Fisher adds to stake in Colgate and Energizer
Ken Fisher (Trades, Portfolio) is the CEO and CIO of Fisher Investments. The investment philosophy at Fisher Investments is based on the idea that supply and demand of securities is the sole determinate of pricing. The following are the companies the investor has been buying for at least the last two quarters. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 23.73
JAZZ's P/E(ttm) is ranked higher than
58% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. JAZZ: 23.73 )
Ranked among companies with meaningful P/E(ttm) only.
JAZZ' s P/E(ttm) Range Over the Past 10 Years
Min: 10.62  Med: 24.95 Max: 99999999.99
Current: 23.73
10.62
99999999.99
Forward P/E 13.00
JAZZ's Forward P/E is ranked higher than
77% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. JAZZ: 13.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.73
JAZZ's PE(NRI) is ranked higher than
57% of the 251 Companies
in the Global Biotechnology industry.

( Industry Median: 27.87 vs. JAZZ: 23.73 )
Ranked among companies with meaningful PE(NRI) only.
JAZZ' s PE(NRI) Range Over the Past 10 Years
Min: 11.75  Med: 24.68 Max: 99999999.99
Current: 23.73
11.75
99999999.99
Price/Owner Earnings (ttm) 32.92
JAZZ's Price/Owner Earnings (ttm) is ranked lower than
53% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. JAZZ: 32.92 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
JAZZ' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.91  Med: 26.87 Max: 432.91
Current: 32.92
8.91
432.91
P/B 4.78
JAZZ's P/B is ranked lower than
63% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. JAZZ: 4.78 )
Ranked among companies with meaningful P/B only.
JAZZ' s P/B Range Over the Past 10 Years
Min: 2.46  Med: 5.48 Max: 32
Current: 4.78
2.46
32
P/S 5.93
JAZZ's P/S is ranked higher than
68% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. JAZZ: 5.93 )
Ranked among companies with meaningful P/S only.
JAZZ' s P/S Range Over the Past 10 Years
Min: 0.21  Med: 5.79 Max: 12
Current: 5.93
0.21
12
PFCF 24.53
JAZZ's PFCF is ranked lower than
55% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. JAZZ: 24.53 )
Ranked among companies with meaningful PFCF only.
JAZZ' s PFCF Range Over the Past 10 Years
Min: 11.77  Med: 18.19 Max: 91.05
Current: 24.53
11.77
91.05
POCF 15.97
JAZZ's POCF is ranked higher than
58% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. JAZZ: 15.97 )
Ranked among companies with meaningful POCF only.
JAZZ' s POCF Range Over the Past 10 Years
Min: 9.59  Med: 15.92 Max: 55.21
Current: 15.97
9.59
55.21
EV-to-EBIT 18.87
JAZZ's EV-to-EBIT is ranked higher than
50% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. JAZZ: 18.87 )
Ranked among companies with meaningful EV-to-EBIT only.
JAZZ' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.5  Med: 16.6 Max: 74.1
Current: 18.87
-8.5
74.1
EV-to-EBITDA 15.61
JAZZ's EV-to-EBITDA is ranked higher than
50% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. JAZZ: 15.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
JAZZ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.9  Med: 13.6 Max: 42.2
Current: 15.61
-10.9
42.2
PEG 0.65
JAZZ's PEG is ranked higher than
84% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. JAZZ: 0.65 )
Ranked among companies with meaningful PEG only.
JAZZ' s PEG Range Over the Past 10 Years
Min: 0.59  Med: 0.81 Max: 8.83
Current: 0.65
0.59
8.83
Shiller P/E 1132.17
JAZZ's Shiller P/E is ranked lower than
98% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.42 vs. JAZZ: 1132.17 )
Ranked among companies with meaningful Shiller P/E only.
JAZZ' s Shiller P/E Range Over the Past 10 Years
Min: 852.5  Med: 984.33 Max: 1150.01
Current: 1132.17
852.5
1150.01
Current Ratio 3.20
JAZZ's Current Ratio is ranked lower than
59% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. JAZZ: 3.20 )
Ranked among companies with meaningful Current Ratio only.
JAZZ' s Current Ratio Range Over the Past 10 Years
Min: 0.2  Med: 2.76 Max: 5.55
Current: 3.2
0.2
5.55
Quick Ratio 3.06
JAZZ's Quick Ratio is ranked lower than
59% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. JAZZ: 3.06 )
Ranked among companies with meaningful Quick Ratio only.
JAZZ' s Quick Ratio Range Over the Past 10 Years
Min: 0.17  Med: 2.59 Max: 5.46
Current: 3.06
0.17
5.46
Days Inventory 107.09
JAZZ's Days Inventory is ranked higher than
59% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. JAZZ: 107.09 )
Ranked among companies with meaningful Days Inventory only.
JAZZ' s Days Inventory Range Over the Past 10 Years
Min: 70.82  Med: 103 Max: 164.69
Current: 107.09
70.82
164.69
Days Sales Outstanding 60.67
JAZZ's Days Sales Outstanding is ranked higher than
52% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. JAZZ: 60.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
JAZZ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.12  Med: 46.23 Max: 60.67
Current: 60.67
30.12
60.67
Days Payable 67.18
JAZZ's Days Payable is ranked higher than
56% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. JAZZ: 67.18 )
Ranked among companies with meaningful Days Payable only.
JAZZ' s Days Payable Range Over the Past 10 Years
Min: 67.18  Med: 81.91 Max: 285.12
Current: 67.18
67.18
285.12

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.90
JAZZ's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. JAZZ: -1.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JAZZ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.4  Med: -15.65 Max: -1.9
Current: -1.9
-32.4
-1.9

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.60
JAZZ's Price/Projected FCF is ranked higher than
75% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. JAZZ: 1.60 )
Ranked among companies with meaningful Price/Projected FCF only.
JAZZ' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.43  Med: 3.08 Max: 68.98
Current: 1.6
1.43
68.98
Price/Median PS Value 1.02
JAZZ's Price/Median PS Value is ranked lower than
55% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. JAZZ: 1.02 )
Ranked among companies with meaningful Price/Median PS Value only.
JAZZ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 1 Max: 1.58
Current: 1.02
0.05
1.58
Price/Peter Lynch Fair Value 0.95
JAZZ's Price/Peter Lynch Fair Value is ranked higher than
68% of the 72 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. JAZZ: 0.95 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
JAZZ' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.85  Med: 1.14 Max: 14.94
Current: 0.95
0.85
14.94
Earnings Yield (Greenblatt) (%) 5.34
JAZZ's Earnings Yield (Greenblatt) (%) is ranked higher than
88% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. JAZZ: 5.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
JAZZ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.3  Med: 5.6 Max: 10.7
Current: 5.34
1.3
10.7
Forward Rate of Return (Yacktman) (%) 33.58
JAZZ's Forward Rate of Return (Yacktman) (%) is ranked higher than
77% of the 122 Companies
in the Global Biotechnology industry.

( Industry Median: 15.82 vs. JAZZ: 33.58 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
JAZZ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -43.1  Med: 1.6 Max: 49.5
Current: 33.58
-43.1
49.5

More Statistics

Revenue (TTM) (Mil) $1,432
EPS (TTM) $ 5.72
Beta1.44
Short Percentage of Float3.48%
52-Week Range $95.80 - 160.00
Shares Outstanding (Mil)59.89

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1,490 1,712 1,930 2,168
EPS ($) 9.87 10.74 12.64 14.22
EPS w/o NRI ($) 9.87 10.74 12.64 14.22
EPS Growth Rate
(3Y to 5Y Estimate)
13.01%
Dividends Per Share ($)
» More Articles for NAS:JAZZ

Headlines

Articles On GuruFocus.com
Cellectar Biosciences' PDC Delivery Platform May Advance Treatment of Multiple Myeloma Feb 13 2017 
Actinium Pharmaceuticals Is Better Than Celator Feb 07 2017 
9 Stocks Trading Below the Peter Lynch Value Jan 11 2017 
Industrial Companies Showing Good Potential for 2017 Jan 04 2017 
Gurus and Insiders Invest in Industrial and Medical Companies Dec 30 2016 
U.S. Elections: What They Might Mean for Investors - JOHCM Commentary Nov 29 2016 
Gurus Invest in Undervalued Biotech Stocks Nov 25 2016 
5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
Stocks Fisher Investments Has Bought for Past 2 Quarters May 03 2016 
Citigroup, Amgen Are Trading With Wide Margin of Safety Mar 30 2016 

More From Other Websites
Jazz Pharmaceuticals to Report 2016 Fourth Quarter and Full Year Financial Results on February 28,... Feb 14 2017
5 Drug Stocks Poised to Beat Earnings Estimates in Q4 Feb 09 2017
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110... Feb 08 2017
Actinium Pharmaceuticals Is Better Than Celator Feb 07 2017
Jazz Pharmaceuticals Manufacturing Plant Gets Warning Jan 27 2017
Jazz Pharmaceuticals Plc: Leads amongst peers with strong fundamentals Jan 19 2017
Can Jazz Pharmaceuticals Be a Top Choice for Value Investors? Jan 19 2017
Jazz Rebuffs Concerns Of Generic Sleep Drug Amid Patent Litigation Jan 18 2017
Wednesday’s Top Biopharma Winners Jan 18 2017
FDA Approves Generic of Jazz Pharma's Sleep Drug Jan 18 2017
Jazz Begins Phase III Study for Label Expansion of Defitelio Jan 18 2017
JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events Jan 18 2017
Neurocrine Med Failure, Jazz Pharma Generic Rival OK Sends Both Down Jan 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)